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Abstract
Background: Activation of microglia, the resident macrophages of the central nervous system (CNS), is the hallmark
of neuroinflammation in neurodegenerative diseases and other pathological conditions associated with CNS
infection. The activation of microglia is often associated with bystander neuronal death. Nuclear factor-B (NF-B) is
one of the important transcription factors known to be associated with microglial activation which upregulates the
expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (Cox-2) and other pro-inflammatory cytokines.
Recent studies have focused on the role of Krüppel-like factor 4 (Klf4), one of the zinc-finger transcription factors, in
mediating inflammation. However, these studies were limited to peripheral system and its role in CNS is not
understood. Our studies focused on the possible role of Klf4 in mediating CNS inflammation.
Methods: For in vitro studies, mouse microglial BV-2 cell lines were treated with 500 ng/ml Salmonella enterica
lipopolysacchride (LPS). Brain tissues were isolated from BALB/c mice administered with 5 mg/kg body weight of
LPS. Expressions of Klf4, Cox-2, iNOS and pNF-B were evaluated using western blotting, quantitative real time PCR,
and reverse transcriptase polymerase chain reactions (RT-PCRs). Klf4 knockdown was carried out using SiRNA
specific for Klf4 mRNA and luciferase assays and electromobility shift assay (EMSA) were performed to study the
interaction of Klf4 to iNOS promoter elements in vitro. Co-immunoprecipitation of Klf4 and pNF-B was done in
order to study a possible interaction between the two transcription factors.
Results: LPS stimulation increased Klf4 expression in microglial cells in a time- and dose-dependent manner.
Knockdown of Klf4 resulted in decreased levels of the pro-inflammatory cytokines TNF-a, MCP-1 and IL-6, along
with a significant decrease in iNOS and Cox-2 expression. NO production also decreased as a result of Klf4
knockdown. We found that Klf4 can potentially interact with pNF-B and is important for iNOS and Cox-2
promoter activity in vitro.
Conclusions: These studies demonstrate the role of Klf4 in microglia in mediating neuroinflammation in response
to the bacterial endotoxin LPS.
Background
Inflammation in brain occurs in several neurodegenera-
tive diseases and in response to pathogens invading the
Central Nervous System (CNS). Several cell types have
been implicated in inflammation mediated neurodegen-
eration, including microglia and astroglia [1]. Microglia,
the resident macrophages of the CNS is the key cell
type which responds to brain injuries or immunological
stimuli such as endotoxins and becomes activated [2,3].
Upon activation, these cells release several pro- and
anti-inflammatory cytokines in order to clear the patho-
gens and cellular debris from the brain tissue [4]. An
exaggerated response by microglia, however, can result
in neuronal damage indirectly by the secretion of cyto-
kines or even directly by the phagocytosis of neurons [5]
which can be detrimental to the normal functioning of
the CNS [2]. Microglia is involved in inflammation
initiated during several neurodegenerative diseases
including Alzheimer’s disease (AD) [6], Parkinson’sd i s -
ease (PD) and multiple sclerosis [7,8]. Understanding
the molecular mechanisms of microglia-associated
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rodegenerative and neuroinflammatory studies.
Microglial response to any pathogenic stimuli including
endotoxins like lipopolysaccharide (LPS) is mediated by
the activation of several pathways and numerous tran-
scription factors. LPS is a major component of outer
membrane of Gram-negative bacteria and it can elicit
strong immune responses in the host [9]. LPS binds to
toll-like receptor 4 (TLR4) on macrophages [10] and can
activate nuclear factor-kappa B (NF-B) [11-13] which is
an important transcription factor in the regulation of pro-
inflammatory enzymes and cytokines. LPS also mediates
the production of inducible nitric oxide synthase (iNOS),
cyclooxygenase-2 (Cox-2) and several pro- and anti-
inflammatory cytokines via phospho NF-B (pNF-B)
activation [14-16]. Recently, a class of zinc-finger tran-
scription factors, Krüppel-like factors (Klfs) have been
reported to play a key role in endothelial and macrophage
mediated inflammation [17-19]. Klfs have three carboxyl
C2H2 zinc-fingers in their DNA binding domain which
has a strong homology with Drosophila melanogaster seg-
mentation protein called Krüppel [20]. These three zinc
fingers are usually found at the C-terminus and bind
to either a CACCC element or GC-box [18]. The N termi-
nus is involved in protein-protein interaction and gene
regulation.
O n eo ft h eK r ü p p e ll i k et r a nscription factors, gut
Krüppel-like factor (GKLF) or Krüppel like factor-4
(Klf4) which was first identified in the epithelial lining
of gut and skin is involved in differentiation and cellular
growth [21,22]. Klf4 is also known to act as a key cell
cycle regulator and a necessary mediator of p53 for the
G1/S and G2/M cell cycle arrest resulting from DNA
damage [23,24]. Klf4 also inhibits differentiation in mur-
ine stem cells [25], and induces pluripotency in mouse
embryonic or adult fibroblasts [26]. In one of the stu-
dies, it was shown to transactivate iNOS promoter by
potentially interacting with p65 of NF-B in response to
several inflammatory stimuli including LPS, tumor
necrosis factor- a (TNF-a)a n di n t e r f e r o n -g (IFN-g)
[18]. The expression of Klf4 significantly reduces upon
treatment with anti-inflammatory tumor growth factor-b
(TGF-b) and upon stimulation with neurotoxic agents
[18,27]. Klf4 also binds to HMGB1 promoter, which is a
cytokine mediator of systemic and local inflammations
and is involved in facilitating its expression, transloca-
tion and release in RAW264.7 macrophages upon LPS
stimulation [28]. However, the role of Klf4 in inflamma-
tion is ambiguous depending on the type of cell it is
expressed in. For example, in endothelial cells, it is
known to suppress inflammation [19] by binding to kal-
listatin, which in turn inhibits TNF-a mediated NF-B
activation and downregulates macrophage chemoattrac-
tant protein-1 (MCP-1) [29]. Lipopolysaccharide-
induced endothelial nitric oxide synthase (eNOS), which
is known to have anti-inflammatory activity, is signifi-
cantly decreased upon Klf4 knockdown. In contrast to
studies on human macrophages [18], in mouse monocy-
tic cells, where Klf4 is shown to be involved in inflam-
matory monocyte differentiation in vivo and in vitro,
Klf4 was not found to be involved in iNOS upregulation
upon LPS stimulation [30]. All these studies indicate
that Klf4 is pleiotropic in nature and its anti-inflamma-
tory or pro-inflammatory functions are cell-type depen-
dent. To date, however, there have been no studies in
order to define the possible roles of Klf4 in microglial
activation and neuroinflammation. Our studies, there-
fore, focus on its putative role in endotoxin-mediated
microglial activation in brain.
In order to study the role of Klf4 in neuroinflammation,
we treated mouse BV-2 cells with LPS to induce acute
inflammation. Our data suggests that Klf4 expression
increases with increasing dose or time of LPS treatment,
and that this is accompanied by increased expression of
iNOS, Cox-2 and several pro-inflammatory cytokines.
Immunofluorescence and immunoblotting studies
revealed that Klf4 translocates to nucleus after LPS treat-
ment in both BV-2 as well as primary microglial cells. As
suggested by knockdown studies, Klf4 plays a key role in
augmenting the pro-inflammatory effects of LPS and
causes microglial activation by upregulating iNOS and
other pro-inflammatory cytokines including TNF-a,
MCP-1 and IL-6. In addition to its role in mediating
iNOS promoter activity, we also show for the first time
that Klf4 is an important transcription factor required for
Cox-2 promoter activity in response to LPS stimulation,
thereby upregulating Cox-2 expression.
Methods
Cells and culture conditions
Mouse microglial cell line BV-2 was a kind gift from
Dr. Steve Levison, University of Medicine and Dentistry,
New Jersey, USA. The cell lines were grown at 37°C in
Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 5% sodium bi-carbonate (NaHCO3), 10%
fetal bovine serum, penicillin at 100 units/ml and strepto-
mycin at 100 μg/ml. All the reagents related to cell cul-
ture were obtained from Sigma Aldrich, St. Louis, USA,
unless otherwise stated. Primary mixed glial cultures
were prepared from P0-P2 mouse brains as described
elsewhere [31,32]. Briefly, P0-P2 BALB/c mouse pups
were sacrificed by decapitation and whole cortex was iso-
lated. The meninges were removed and the tissues were
enzymatically digested using trypsin-DNAse. After a brief
mechanical dissociation, the cell suspension was passed
through 100 mm cell strainers and then centrifuged at
400 g for 7.5 min. The cells were counted using hemocyt-
ometer and were plated into 75 cm
2 tissue culture flasks
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5 viable cells/cm
2 in minimum
essential medium (MEM) supplemented with 10% fetal
bovine serum, penicillin at 100 units/ml, and streptomy-
cin at 100 μg/ml, 0.6% glucose and 2 mM glutamine.
Exhausted media was replenished with fresh media every
2-3 days after plating. On day 12, when the mixed glial
culture was confluent, the flasks were shaken on an
Excella E25 (New Brunswick Scientific, NJ, USA) orbital
shaker at 250 rpm for 60-75 min to dislodge microglial
cells. The non-adherent cells obtained after shaking were
plated in bacteriological petridishes for 60-90 min to
allow microglial cells to adhere. The adherent cells were
scraped, centrifuged and plated in chamber slides at 8 ×
10
4 viable cells/cm
2, and incubated at 37°C for 30 min to
allow microglial cells to adhere.
LPS administration to animals
T h r e eg r o u p so f6 - 8w e e k so l dB A L B / cm i c ew e r e
injected intraperitoneally with 5 mg/kg body weight of
Salmonella enterica LPS dissolved in 1X PBS. Control
animals received only 1X PBS. All the animals of each
group were sacrificed at different time point of 3 h, 6 h,
12 h, 24 h and 48 h either for tissue or protein. All
experiments were performed according to the protocol
approved by the Institutional Animal Ethics Committee.
Knockdown experiments
Short interfering RNA (SiRNA) against mouse Klf4
(sense: 5’- UCC AAA GAA GAA GGA UCU CUU- 3’)
and scrambled SiRNA (ScRNA) (sense: 5’-G U GC A C
AUG AGU GAG AU UU- 3’) were designed using an
online SiRNA design software (Ambion, Applied biosys-
tems, Austin, USA) and were synthesized by Dharmacon
RNAi technologies (Thermo fisher Scientific, USA). 100
nM of Klf4 SiRNA was used for transfection using Lipo-
fectamine RNAi max (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. Briefly, BV-2
cells were seeded and maintained in sets of three at
37°C and 5% CO2 and when the cells were 70% to 80%
confluent, they were transfected in Opti-MEM (Invitro-
gen) for 6 hours after which fresh 5% DMEM was
added to the cells for 30 hours. The specificity of the
antisense oligo was validated by using 100 nM of
ScRNA and the control group (C) was treated with lipo-
fectamine alone. The cells were then treated with 500
ng/ml of LPS for either 3 h for the analysis of changes
in Klf4 mRNA levels by q(RT)-PCR or for 12 hours to
analyse any changes in protein in order to perform
immunoblotting and cytokine bead arrays (CBA).
Luciferase assay
For luciferase assays, luciferase reporter gene constructs
pGL2-iNOS (kindly provided by Dr. Mark A. Feinberg
and Dr. Mukesh K. Jain, Harvard Medical School,
Boston, MA, USA. The construct was originally made
by Dr. Mark A. Perella, Harvard Medical School, Boston,
MA, USA) [18,33] and pCOX301 (a kind gift from Dr.
Manikuntala Kundu, Bose Institute, Kolkata, India) [34]
were used that contained the 1,516 bp region from
mouse iNOS 5’flanking region (-1485 bp to +31 bp
region inserted in HindIII at 3’and KpnI at 5’ sites
which removes SV40 promoter upstream to luciferase
gene from the construct) and Cox-2 promoter region
(-891 bp to +9 bp region also inserted using HindIII at
3’a n dK p n Ia t5 ’ end) cloned upstream of luciferase
reporter gene in pGL2-promoter and pGL2-basic vector
r e s p e c t i v e l y( P r o m e g a ,M a d i s o n ,W I ,U S A ) .A f t e r
24 hours of SiRNA and ScRNA transfection, 1 μgo f
these plasmids were used for transfection using 5 μlo f
lipofectamine 2000 (Invitrogen) in Opti-MEM for
6 hours. The cells were then maintained for additional
12 hours in 5% DMEM before the cells were treated
with 500 ng/ml of LPS.
The luciferase assay was carried out using luciferase
assay kit (Promega) according to manufacturer’sp r o t o -
col. Briefly, the cells were washed with 1X PBS and
lysed in reporter lysis buffer provided by the kit and
centrifuged at 12,000 g for 5 minutes at 4°C and super-
natant was collected. 100 μl of luciferase assay reagent
was dispensed into three sets of luminometer tubes and
20 μl of the collected supernatant was added to each
tube and the reading was taken using Sirius single tube
luminometer (Berthold detection systems GmBH,
Germany). The luciferase units were measured as Rela-
tive Luciferase Units (RLU) and these values were nor-
malized to the amount of protein present in the sample.
Nitrite measurement
Nitrite generation by BV-2 cells was used as an indica-
tor of NO release and measured by the Griess reaction
as described elsewhere [31]. Briefly, the media from
treated cells was centrifuged at 2,000 rpm for 5 min at
4°C to remove cellular debris. 50 μlo ft h i sm e d i aw a s
incubated for 15 min at room temperature in dark
with 50 μl of Griess reagent (sulfanilamide and N-1-
napthylethylenediamine dihydrochloride) (Sigma
Aldrich) under acidic (phosphoric acid) conditions in
order to measure the nitrite content. The readings
were taken spectrometrically at 540 nm using micro-
plate spectrophotometer (Biorad, Australia) and the
concentration was calculated from a sodium nitrite
standard reference curve.
Immunoblotting
For in vivo studies, the whole brain tissues (except olfac-
tory lobes and hind brain) from three different animals
after 3 h, 6 h, 12 h, 24 h and 48 h post LPS administra-
tion and untreated controls were dissected and placed
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pared 1X PBS containing 20 μl of protease inhibitor
(Sigma Aldrich). Samples were homogenized and centri-
fuged at 8,000 g for 20 min. Supernatants were collected
and protein concentrations were determined using a
bicinchoninic assay (BCA) method.
For in vitro studies, control and treated BV-2 cells
were harvested using ice-cold 1X PBS. In order to iso-
late total cellular extracts, the cells were lysed in buffer
containing 1% Triton-X-100, 10 mM Tris-HCl (pH 8.0),
150 mM NaCl, 0.5% Nonidet P (NP-40), 1 mM EDTA,
0.2% EGTA, 0.2% sodium orthovanadate and protease
inhibitor cocktail (Sigma Aldrich). For nuclear extracts,
BV-2 cells were collected with 1X PBS and harvested by
spinning at 2000 rpm for 5 min. The cells were resus-
pended in 400 μlo fc o l db u f f e rA( 1 0m MH E P E Sp H
7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM
DTT and 0.5 mM PMSF) and then kept on ice for
15 min. 15 μl of nonionic surfactant, IGEPAL CA 630
(Sigma Aldrich) was then added and vortexed vigor-
ously. The cells were then pelleted for 1 min at 10,000 g
and the recovered pellet was resuspended in 50 μlo fi c e
cold buffer B (20 mM HEPES pH 7.9, 400 mM KCl and
1 mM EDTA) and subjected to gentle shaking for
15 min at 4°C. The suspended cells in Buffer B were
again pelleted at 4°C and the supernatant having the
nuclear protein was collected and estimated by bicinch-
oninic assay (BCA) method.
30 μg of each protein sample was electrophoresed on
a 7.5%-10% sodium dodecyl sulfate-polyacrylamide gel
(SDS-PAGE) and transferred onto a nitrocellulose mem-
brane. The membrane was then blocked in 5% skimmed
milk in 1X PBS-Tween-20 (1X PBST) for 4 h at room
temperature with gentle agitation. After blocking, the
blots were incubated with rabbit anti-Klf4 (Chemicon
International, CA, USA) at a dilution of 1:500 in 1%
BSA in 1X PBST overnight at 4°C with gentle agitation.
After five washes of five minutes each in 1X PBST, blots
were then incubated with goat anti-rabbit horseradish
peroxidase (Vector Laboratories, CA, USA) at a dilution
of 1:5,000 in 1X PBST for 1.5 h, with agitation. The
blots were rinsed again in 1X PBST. The blots were
developed by using chemiluminescence reagent (Milli-
pore, MA, USA) and exposing them to Chemigenius,
Bioimaging System (Syngene, Cambridge, UK). The
images were captured and analysed using the Genesnap
and Genetools software respectively from Syngene. The
blots were stripped for 30 min at 50°C in stripping buf-
fer which contained 62.5 mmol/L Tris-HCl, pH 6.8, 2%
SDS, 100 mmol/L 2-mercaptoethanol. The stripped
blots were probed with anti-b-tubulin (1:1,000; Santa
Cruz Biotechnology, CA, USA) or anti-b-actin (1:10,000;
Sigma Aldrich) to determine equivalent loading of total
cell extracts and nuclear extracts respectively. Similarly,
blots were developed for rabbit anti-iNOS (1:1000, Milli-
pore), Cox-2 (1:1000, Millipore) and pNF-B (1: 1,000;
Ser-536; Cell Signaling technology, MA, USA) using the
secondary goat anti-rabbit HP (1:5,000, Vector Labora-
tories). The protein levels were normalized with either
b-tubulin or b-actin levels.
Immunocytochemistry
BV-2 cells and mouse primary microglial cells were pla-
ted on chamber slides in sets of three and allowed to
adhere for 12 h. The cells were fixed in 4% PFA for
20 min at 25°C, following which they were incubated in
blocking solution for 1 h at 25°C. They were then
stained with rabbit anti-Klf4 (1:250, Millipore) overnight
at 4°C. After PBS washes, the anti-rabbit FITC conju-
gated secondary antibody (1: 250, Vector Laboratories)
were added for 1.5 h and then mounted with 4, 6-diami-
dino-2-phenylindole (DAPI). Images were obtained
using Zeiss Apotome microscope (40X magnification;
Zeiss, Germany).
Immunohistochemistry
12 h and 48 h LPS treated and age matched control
BALB/c mice in sets of three were perfused transcar-
dially with 1X PBS and whole brains isolated were fixed
with 4% paraformaldehyde (PFA) in 1X PBS for 24 h at
4°C and subsequently kept in 30% sucrose for additional
24-48 h at 4°C or until the tissue is immersed at the
bottom of the tube. The brains were then processed for
cryostat sectioning and the sections were stained for
Klf4 and Iba1, a marker of activated microglia. Briefly,
the cryostat sections were washed with 1X PBS and pro-
cessed for antigen retrieval by incubating at 70°C for 1 h
in antigen unmasking solution (Vector laboratories). The
sections were then washed with 1X PBS and blocked for
1.5 h with 5% BSA in 1X PBS. Microglia were labeled
with rabbit anti-Iba1 antibody (1:250; Wako, Japan),
along with mouse anti-Klf4 (1:100, Santa Cruz biotech-
nology) by incubating the sections overnight at 4°C.
After five washes with 1X PBS, the sections were incu-
bated with goat anti-rabbit Alexa Fluor 594 (1:1000;
Molecular Probes, Oregon, USA) for Iba1 and horse
anti-mouse Fluorescein Isothiocyanate (FITC, 1:250;
Vector Laboratories) for Klf4 for 1.5 h. The slides were
then mounted with mounting medium containing DAPI
(Vector laboratories). The stained slides were observed
under the Zeiss Axioplan 2 Fluorescence microscope
(20X magnification; Zeiss, Germany). Higher magnifica-
tion images were captured with Zeiss LSM 510 confocal
microscope (40X magnification; Zeiss, Germany).
Co-immunoprecipitation
In order to study the interaction between pNF-Ba n d
Klf4, co-immunoprecipitation was carried out using
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of pNF-B antibody (Cell signaling technologies) and 1
μg of rabbit IgG (Vector laboratories) in IP buffer con-
taining 50 mM Tris-Cl pH 8.0, 150 mM NaCl, 10% gly-
cerol, 1 mM Phenyl methyl sulfonyl fluoride (PMSF)
and 0.5% Triton X-100 at 4°C overnight with gentle
shaking. The Sepharose G beads (GE healthcare bios-
ciences AB, Uppsala, Sweden) were calibrated with IP
buffer and 30 μl of the slurry was then added to the
protein-antibody mixtures for 4 h at room temperature
with gentle rocking. The beads were then pelleted at
12,000 g for 2 min and washed four times with 600 μl
of ice cold IP buffer after discarding the supernatant.
The sample buffer was then added to each sample bead
and loaded onto gel for immunoblotting.
Reverse transcriptase PCR (RT-PCR) and quantitative real-
time (qRT)-PCR
BV-2 cells, following treatment were washed twice with
1X PBS and lysed in Trizol reagent (Sigma Aldrich) as
per the manufacturer’sp r o t o c o l .T h eR N Aw a si s o l a t e d
by phenol-chloroform method and it was quantified
using spectrophotometer (GE healthcare biosciences AB,
Uppsala, Sweden). RT-PCR was performed using the
onestep RT-PCR kit (Qiagen Biosciences; Hamburg,
Germany) following the manufacturer’sp r o t o c o lo n
Genius Techne thermal cycler as described earlier [35].
Briefly, 500 ng of the total RNA was used as template in
25 μl PCR reactions, containing 5X PCR buffer (5 μl),
dNTPs (1 μl), enzyme mix (1 μl) and specific forward
and reverse primers (0.5 μM) and RNase free water. Oli-
gonucleotide primer specific for mouse iNOS (forward:
5’-CCC CCG AAG TTT CTG GCA GCA GC-3’,
reverse: 5’-GGC TGT CAG AGC CTC GTG GCT TTG
G- 3 ’, annealing temperature: 62°C, 35 cycles, amplicon
size: 468 bp), Cox-2 (forward: 5’-AAG GCC TCC ATT
GAC CAG -3’, reverse: 5’- TCT TAC AGC TCA GTT
GAA CGC -3’, annealing temperature: 56°C , 35 cycles,
amplicon size: 512 bp) and cyclophilin mRNAs (forward:
5’-CCA TCG TGT CAT CAA GGA CTT CAT -3’,
reverse: 5’-TTG CCA TCC AGC CAG GAG GTC T -3’,
annealing temperature: 58°C , 35 cycles, amplicon size:
192 bp) were procured from Microsynth (Balgach, Swit-
zerland). PCR products were separated on 1.5% - 2%
agarose gel, stained with ethidium bromide, and photo-
graphed using GeneSnap software provided with Chemi-
genius Bioimaging System, Syngene. Photographs were
analyzed by GeneTools software provided with same
Bioimaging System. The mRNA levels were normalized
to cyclophilin.
For performing q(RT)-PCR for Klf4 mRNA, Klf4 pri-
mers (forward: 5’-TGC CAG ACC AGA TGC AGT
CAC- 3’,r e v e r s e :5 ’-GTA GTG CCT GGT CAG TTC
ATC- 3’, annealing temperature: 60°C, 35 cycles,
amplicon size: 286 bp) were procured from Sigma.
SYBR Green Supermix (Bio-Rad, Hercules, CA) was
used and 500 ng of cDNA was used as a template on
ABI Prism 7700 sequence detection system (Applied
Biosystems, Foster City, CA). The conditions used for
real time PCR have been described earlier [36] and were
as follows: 95°C for 3 min (1 cycle), 94°C for 20 s, 60°C
for 30 s, and 72°C for 40 s (40 cycles). The dissociation
curves were generated to check for the specificity of pri-
mer annealing to the template. The real time PCR
results were normalized to 18S rRNA internal control
and quantified using comparative Ct method (2
-[Δ][Δ]Ct)
[37] and analyzed using the iCycler Thermal Cycler
Software (Applied Biosystems).
Cytokine bead array (CBA)
A CBA mouse inflammation kit (BD Biosciences, NJ,
USA) was used to quantitatively measure cytokine levels
in the control and LPS treated BV-2 cells. Using 50 μl
of mouse inflammation standard and sample dilutions,
the assay was performed according to the manufac-
turer’s instructions and analyzed on the FACS Calibur
(Becton Dickinson). This method quantifies soluble par-
ticles, in this case cytokines using a fluorescence based
detection mechanism. The beads, coated with IL-6,
TNF-a and MCP-1 react with test lysates and standards,
to which fluorescence dyes are then added. Analysis was
performed using CBA software that allows the calcula-
tion of cytokine concentrations in unknown lysates
[35,38].
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as described elsewhere [39] using
LightShift Chemiluminescent EMSA Kit (Pierce Biotech-
nology, Thermo Fisher Scientific Inc., Rockford, USA).
Briefly, 100 femtomoles of biotin labeled and 100-molar
excess of unlabelled Oligonucleotide (Cold probe) corre-
sponding to iNOS-binding sequence (5- CTG CCT
AGG GGC CAC TG -3) were used (Sigma Proligo,
Singapore). Nuclear extract (5 μg) isolated from LPS-
treated BV-2 cells was pre- incubated with anti-Klf4 Gel
shift transcruze antibody (1 μg; Santa Cruz Biotechnol-
ogy) for 1 h at 4°C. Biotin-labeled probes were added
for additional 30 min at room temperature. After elec-
trophoresis on 6% polyacrylamide gel, the samples on
gel were transferred onto a presoaked positively charged
nylon membrane (Roche diagnostics, GmBH, Germany).
The ultra violet cross linking was carried out using UV
cross linker (UVC 500, Hoefer scientific, USA). The
blots were then incubated in blocking buffer for 15 min
followed by incubation with streptavidin-horseradish
peroxidase (1:300; HRP) conjugate solution for addi-
tional 15 minutes with gentle shaking. After washing
with wash buffer supplied by the manufacturer, the
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buffer for five min followed by addition of Enhanced
Chemiluminiscent reagent (ECL) supplied by the manu-
facturer. The blot was developed by exposing it to
Chemigenius, Bioimaging System (Syngene).
Statistical Analysis
All the experiments were performed in sets of three
unless otherwise mentioned and the data generated
were analyzed statistically by paired two-tailed Student’s
t-test. A statistical p-value of 0.01 and 0.05 were consid-
ered significant.
Results
Dose and time dependent increase in Klf4 levels in BV-2
cells in total cell extract
Any changes in Klf4 in microglia in response to endo-
toxins have not been reported till now. Therefore, we
investigated whether mouse microglial BV-2 cells
express Klf4 and how its expression profile changes in
response to LPS treatment. BV-2 cells were treated with
LPS in a dose- and time-dependent manner in order to
detect any change in the expression levels of Klf4. For
dose-dependent studies, three different doses of 100 ng/
ml, 250 ng/ml and 500 ng/ml of LPS were given for
12 hours. Increased expression of Klf4 was observed at
100 ng/ml dose, and it gradually increased with higher
doses, the maximum expression being at 500 ng/ml LPS
where a 3-fold increase was observed over control, (p <
0.01) (Fig 1A). Since this dose is in agreement with
many inflammation studies, we therefore chose 500 ng/
ml LPS for carrying out treatments in the rest of our
experiments. Five different time points of 1 h, 3 h, 6 h,
12 h and 24 h were chosen for time dependent studies
for the analysis of Klf4 expression. We observed that
there was no significant change in the levels of Klf4
expression in total cellular extracts after 1 h of LPS
treatment, however a gradual increase was observed at
later time points. After 3 hours of LPS treatment an
increase of about 1.5 times to that of control was seen
(p < 0.05) and the levels of Klf4 expression were found
to be maximum at 12 h and 24 h time points when
more than 2.5-fold increase over that of control was
observed (p < 0.01) (Fig 1B).
LPS treatment increases the expression of inflammatory
mediators, iNOS, Cox-2 and pro-inflammatory cytokines in
BV-2 mouse microglial cells
In order to confirm the onset of inflammation in BV-2,
we next investigated the expression levels of pro-
inflammatory effector enzymes, iNOS and Cox-2 in a
dose and time-dependent manner upon LPS treatment.
This study was carried out using the same doses and
four different time points except for 1 h time point
where we did not notice any considerable change in
Klf4 expression. We observed a gradual increase in the
levels of both iNOS and Cox-2 with increasing dose
and time of LPS treatment. Significant 4-fold increase
in iNOS expression with 500 ng/ml LPS dose after
12 hours of stimulation was observed which was found
significant with respect to control (p < 0.01) (Fig 1C).
The expression of iNOS increased at earlier time
points of 3 and 6 hours of LPS treatment and this
increase was also found to be significant with respect
to control (p < 0.01) (Fig 1C). Similarly, Cox-2 expres-
sion also increased by more than 5-fold with respect to
control after 12 hours of LPS treatment (p < 0.01)
(Fig 1D). This increase in iNOS and Cox-2 levels were
found to be significant even after 24 hours of LPS sti-
mulation (p < 0.01). Microglial activation and neuroin-
flammation is also associated with the release of
several pro-inflammatory cytokines and chemokines.
CBA using BV-2 cell lysates was performed to test any
changes in the levels of key pro-inflammatory cyto-
kines and chemokines, TNF-a,M C P - 1a n dI L - 6u p o n
LPS stimulation. We observed a significant increase
the levels of these mediators with increasing time
point. The levels of TNF-a,a na c u t ep h a s ep r o t e i n
that is secreted by macrophages and microglia in
response to pathogenic stimuli, increased by more than
10-folds and reached up to 5,000 pg/ml (p < 0.01) at
3 h which was significant with respect to control and
by 12 h, the levels were maintained at 4,000 pg/ml
(p < 0.01) (Fig 1E). MCP-1, a chemokine which is
known to recruit inflammatory cells into CNS par-
enchyma [40], was recorded to be around 3,000 pg/ml
at 12 h of LPS stimulation which was 3 times more
than control levels (p < 0.01) (Fig 1F). Another pro-
inflammatory cytokine, IL-6 which is pleotropic in nat-
ure [41,42] is known to increase dramatically in
response to inflammation and CNS injury. The levels
of IL-6 also increased to 4,000 pg/ml in response to
LPS stimulation which is an increase of about 4-fold
with respect to control at all the time points (p < 0.01)
(Fig 1G). We observed that the increase in expression
levels of Cox-2, iNOS and other pro-inflammatory
cytokines were corresponding to the levels of Klf4
which indicates that this transcription factor might
h a v ear o l ei nm e d i a t i n gi n f l a m m a t o r yr e s p o n s ei n
BV-2 following LPS stimulation.
Increase in nuclear Klf4 upon LPS stimulation in vitro
In order to evaluate Klf4 levels in nucleus following LPS
stimulation, nuclear extract from BV-2 cells treated with
LPS for different time points of 1 h, 3 h, 6 h, 12 h and
24 h was isolated and analyzed for Klf4 protein expres-
sion by performing western blots. A significant 2-fold
increase in Klf4 levels was observed at 1 h and 3 h time
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Page 7 of 20Figure 1 Klf4 expression and inflammation in BV-2 microglial cells upon LPS stimulation. Total cellular extract isolated from cells treated
with different doses of LPS and for different time points were analyzed by immunoblot. (A and B) A significant increase is seen in Klf4
expression in a dose-dependent (A) and time dependent-manner (B) compared to untreated control samples. (C and D) There are significant
increases in iNOS and Cox-2 levels in dose- (C) and time-dependent (D) manners in cells treated with LPS. The graphs represent protein levels
relative to untreated controls. (E-G) Increase in pro-inflammatory cytokines upon LPS stimulation. Cytokine bead arrays were carried out to
estimate the concentrations of TNF-a (E), MCP-1 (F) and IL-6 (G) in BV-2 cells treated for different time points. There were significant increases in
all of these pro-inflammatory cytokines upon LPS treatment. Absolute values of these cytokines are given as pg/ml. *, **, Statistical differences in
comparison to control values (*p < 0.05; **p < 0.01).
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increased level of Klf4 was maintained even at later time
points with more than 1.5-fold increase even at 12 h
time point (p < 0.05).
In order to study the nuclear translocation of Klf4, we
carried out immunostaining in LPS treated BV-2 micro-
glial cell line and mouse primary microglia for different
time durations. We found that in BV-2 cells Klf4 trans-
locates to nucleus as early as 3 h which can be seen till
12 h (Fig 2B). It is seen localized to specialized regions
in the nucleus which probably are transcriptionally
active regions or nucleoli. Similarly, in primary micro-
glia, after 3 h and 6 h of LPS treatment, the expression
of Klf4 increases and is perinuclear in location which at
Figure 2 Nuclear expression and translocation of Klf4 in response to LPS. Immunoblotting was carried out for nuclear extracts from LPS-
treated BV-2 cells in a time-dependent manner. (A) A significant increase is observed in Klf4 levels in nuclear extracts at the 1 h and 3 h time
points. The graph represents nuclear Klf4 protein levels relative to untreated controls. *, **, Statistical differences in comparison to control values
(* p < 0.05; ** p < 0.01). For nuclear translocation studies, immunofluorescence for Klf4 was carried out in BV-2 cells and primary microglia. (B)
Increased expression and nuclear translocation of Klf4 in BV-2 cells at 3 h, 6 h and 12 h time points, indicated by arrows. (C) Increased
expression of Klf4 in mouse primary microglia cells and nuclear localization of Klf4 at the 12 h time point are indicated by arrows. Scale bar:
20 μm.
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Page 9 of 2012 h time point translocates to nucleus (Fig 2C). This
study reveals that Klf4 migrates to nucleus at earlier
time points and as a transcription factor probably has a
role in onset of inflammation.
LPS induces Klf4 expression in vivo
We wanted to investigate if LPS treatment increases Klf4
expression in microglia in vivo as well. Increase in Klf4
expression was observed in total protein extracts from
the brains of mice treated with LPS over control. This
increase, although, was not gradual with increasing time
points but was significantly higher at all the time points
with respect to control (Fig 3A). At 6 h time point, 2-fold
increase in Klf4 expression with respect to control was
observed (p < 0.01) (Fig 3A). This increase corresponded
with the elevated levels of pro-inflammatory cytokines
from these mice (data not shown). We also estimated the
levels of pNF-B at all the time points and found that its
levels significantly increased over that of control with
maximum increase noticed at 6 h and 12 h (p < 0.01)
(Fig 3B). Immunohistochemistry also confirmed the
expression of Klf4 in microglial cells. Numerous Iba1
positive cells with activated morphology were observed
in LPS treated sections at all time points. Analysis of 12 h
and 48 h brain sections from mice treated with LPS
revealed the co-localization of Klf4 with Iba1 positive
microglia (Fig 3C). Individual cells imaged using high
resolution confocal microscopy also confirms Klf4
expression in these Iba1 positive cells (Inset).
Knockdown of Klf4 and subsequent decrease in
production of pro-inflammatory cytokines
In order to confirm the role of Klf4 in mediating inflam-
mation, we carried out knockdown of Klf4 transcription
factor using SiRNA directed against its mRNA in BV-2
cells in both LPS (Si+LPS) treated and untreated
(Si-alone) conditions. Cells were also transfected with
ScRNA in both LPS treated (Sc+LPS) and untreated
(Sc-alone) sets. To confirm the knockdown, we per-
formed a quantitataive Real Time (qRT)-PCR for Klf4
mRNA along with an immunoblot for Klf4 and found a
significant more than 2.5-fold decrease in Klf4 mRNA in
SiRNA transfected samples upon LPS treatment (Si+LPS)
compared to LPS alone treated cells (p < 0.01) (Fig 4A).
Significant 1.4-fold decrease was also confirmed at the
protein level where the Klf4 protein level was signifi-
cantly reduced in Si+LPS cells (p < 0.05) (Fig 4B) with
r e s p e c tt oL P St r e a t e dc e l l s .N os i g n i f i c a n tc h a n g e si n
Klf4 mRNA or protein level was noticed upon LPS treat-
ment in ScRNA transfected (Sc+LPS) with respect to LPS
alone condition. There was no significant change
observed in either Si-alone or Sc-alone treatments with
respect to untreated control cells and their values were
found to be comparable to these controls.
Considering the potential role of Klf4 in inflammation,
we hypothesized that Klf4 may play a role in the upre-
gulation of cytokines such as TNF-a,M C P - 1a n dI L - 6 .
Since there was no significant change in Klf4 levels in
either Si-alone or Sc-alone conditions with respect to
untreated controls, rest of the experiments did not
include these conditions and only untreated cells served
as control. CBA analysis was carried out to evaluate the
levels of these cytokines after 12 hours of LPS treatment
in BV-2 cells. As we have noticed earlier, the levels of
all the cytokines in LPS treated cells were significantly
elevated with respect to that of control. However, in Si
+LPS cells, a significant reduction in their levels with
respect to LPS and Sc+LPS cells was found. TNF-a
levels were significantly reduced by about 2-fold in Si
+LPS cells (p < 0.01) (Fig 4C). A similar 2-fold reduc-
tion was also observed in MCP-1 levels in Si+LPS cells
transfected samples when compared to LPS alone trea-
ted cells (p < 0.01) (Fig 4D). The CBA also revealed a
significant reduction by more than 2-fold in IL-6 levels
when compared to Sc+LPS and LPS alone treated sam-
ples (p < 0.01) (Fig 4E). We can therefore conclude
from these observations that Klf4 plays an important
role in mediating inflammation as knocking it down sig-
nificantly reduces the production of pro-inflammatory
cytokines in BV-2 microglial cells.
Klf4 knockdown results in decreased iNOS expression and
NO production
Klf4 regulates iNOS levels in human macrophages [18].
However, its role in microglial activation is not known,
we therefore, wanted to evaluate iNOS expression upon
Klf4 knockdown in BV-2 cells. We carried out semi-
quantitative RT-PCR in order to estimate the iNOS
mRNA levels. Since we did not observe any significant
change in the levels of Klf4 in Si-alone and Sc-alone
conditions, we transfected cells with both SiRNA and
ScRNA and treated them with LPS. A significant 2-fold
decrease in iNOS mRNA levels in Si+LPS cells was
found with respect to LPS and Sc+LPS cells (p < 0.01)
(Fig 5A). We also noticed a significant decrease in iNOS
protein levels as confirmed by immunoblot analysis
which showed significant 2-fold over LPS treated sam-
ples (p < 0.01) (Fig 5B). Since Klf4 knockdown resulted
in decreased production of iNOS, we also estimated the
levels of nitric oxide (NO) a product generated by
iNOS. NO was measured by estimation of nitrites (a
stable product of NO) in the supernatants from differ-
ently treated BV-2 cells. The colorimetric analysis of
nitrite production was carried out by adding Griess
reagent to these supernatants. The concentration of
nitrite in cell supernatants of LPS and Sc+LPS cells was
markedly elevated after 12 h of LPS treatment (p < 0.05)
(Fig 5C). We noticed that Klf4 knockdown resulted in a
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Page 10 of 20Figure 3 Klf4 expression in vivo upon LPS administration. Immunoblot and immunohistochemistry analysis of Klf4 expression in BALB/c mice
brains upon LPS administration. (A) There are significant increases in Klf4 expression at different time points compared to control brain. (B) There
is a significant increase in pNF-B levels upon LPS administration in a time-dependent manner compared to control brain. The graphs represent
pNF-B and Klf4 protein levels in brains of LPS-treated mice relative to control mouse brain. *, **, Statistical differences in comparison to control
values (* p < 0.05; ** p < 0.01). (C) Fluorescent microscopy images of Klf4 expression in microglial cells in brain cortices of control and LPS-
treated mice. Klf4 (FITC, green) co-localizes with Iba1- (Alexa Fluor 594, red) positive microglial cells at 12 h and 48 h after LPS administration.
Co-localization is shown by arrows in the merged images. Inset. The inset depicts high resolution confocal images of Klf4 and Iba1 co-
localization (yellow) in single cells at the 12 h and 48 h time point. Data represent groups of 3 animals per treatment. Scale bar: 50 μm.
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Page 11 of 202-fold reduction in NO levels (p < 0.05). This indicates
that Klf4 regulates the expression of iNOS and its
inflammatory mediators.
Klf4 regulates iNOS promoter activity in BV-2 microglial
cells
Klf4 has been shown to bind to the iNOS promoter in
human macrophages upon LPS and IFN-g treatment
[18]. Since we saw a decrease in iNOS levels upon Klf4
knockdown in microglial cells and that iNOS is mostly
regulated at the transcriptional level [43], we wanted to
know if Klf4 also interacts with iNOS promoters in
microglial cells upon endotoxin stimulation. Interaction
of Klf4 to iNOS promoters was assessed using iNOS-
pGL2 luciferase construct that has firefly luciferase
directly driven by iNOS promoter. This assay was car-
ried out for untreated control as well as LPS, Si+LPS
and Sc+LPS treated BV-2 cells. We found that in LPS
and Sc+LPS treated cells, the promoter activity
measured in terms of relative luciferase units increased
significantly with respect to control (p < 0.01) but
decreased significantly by 5-folds in Si+LPS treated cells
(p < 0.01) (Fig 5D). This finding suggests that Klf4 is an
important transcription factor required for iNOS pro-
moter activity and considering its role as a transcription
factor, it may interact with iNOS promoter in microglial
cells upon LPS stimulation.
In order to confirm this, we then carried out electro-
mobility shift assay (EMSA) using the biotinylated iNOS
probe for -212 bp position of iNOS promoter (5- CTG
CCT AGG GGC CAC TG -3). This sequence was found
to be important for Klf4 binding to iNOS promoter and
it is close to pNF-kB binding site on this promoter [18].
In this experiment, nuclear extracts were isolated from
12 h LPS treated sample and incubated with the biotiny-
lated iNOS probe along with or without the cold probe.
This resulted in a ‘shift’ (Lane 2) with respect to probe
alone (Lane 1). Addition of anti-Klf4 antibody resulted
Figure 4 Role of Klf4 in mediating inflammation. Knockdown of Klf4 in BV-2 mouse microglial cells using SiRNA against Klf4 mRNA and
subsequent decrease in the expression of pro-inflammatory cytokines. (A) q(RT)-PCR demonstrate a significant decrease in Klf4 mRNA levels in Si
+LPS cells compared to LPS alone-treated cells. Cells treated with lipofectamine alone served as controls. The graph represents relative Klf4
mRNA expression values normalized to 18S rRNA internal control. (B) Immunoblot analysis of Klf4 protein isolated from BV-2 cells. Klf4 protein
levels were decreased significantly in the Si+LPS group compared to LPS alone and to the Sc+LPS group. The graph represents Klf4 protein
levels normalized to b-tubulin. No significant differences were observed in Si-alone and Sc-alone conditions compared to control cells for both
mRNA and protein levels. (C-E) Cytokine bead array analysis of pro-inflammatory cytokines upon Klf4 knockdown. There is a more-than-two-fold
decrease in TNF-a (C) and MCP-1 (D) levels in Klf4 knockdown samples, and a significant three-fold decrease is noticed in the case of IL-6 (E).* ,
**, Statistical differences in comparison to control values (* p < 0.05; ** p < 0.01) and #, Statistical differences with respect to LPS treated values,
(# p < 0.01).
Kaushik et al. Journal of Neuroinflammation 2010, 7:68
http://www.jneuroinflammation.com/content/7/1/68
Page 12 of 20Figure 5 Role of Klf4 in iNOS expression upon LPS stimulation. (A) RT-PCR for iNOS mRNA demonstrates a significant decrease in iNOS
mRNA levels upon Klf4 knockdown compared to LPS-treated cells. (B) Immunoblot showing iNOS levels under different conditions. There is a
significant decrease in iNOS proteins levels in Si+LPS cells compared to LPS-treated cells. The graphs represent relative iNOS mRNA and protein
levels with respect to the untreated controls. (C) Nitrite assay using Griess reagent was carried out to measure iNOS activity. A significant
reduction is noticed in NO production as a result of Klf4 knockdown in LPS-treated samples. (D) Luciferase assay for iNOS promoter activity. Data
is represented as relative luciferase units/amount of protein (in μg). A more-than-3-fold decrease is observed in luciferase activity in Si+LPS cells
compared to LPS-treated cells. (E) EMSA carried out with nuclear extracts of control and LPS-treated BV-2 cells. Lane 1 shows free iNOS probe,
whereas a shift is noticed in lane 2 when nuclear extracts were incubated with the probe. Lane 3 shows a supershift when Klf4-specific antibody
was incubated with the probe and the nuclear extracts. The shift and supershift are indicated by arrows. Lane 4 shows a decreased shift when
nuclear extracts from unstimulated control BV-2 cells were incubated with the iNOS probe. In lane 5, in addition to biotinylated probe, a 100-
molar excess of unbiotinylated (Cold) probe was added along with nuclear extracts from LPS-stimulated cells. No significant band is observed in
this lane. *, **, Statistical differences in comparison to control values and #, Statistical differences with respect to LPS-treated values respectively
(* p < 0.05, ** p < 0.01, # p < 0.01).
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tein-DNA complex (Lane 3; Fig 5E). We also carried out
EMSA with nuclear extracts from unstimulated control
cells and observed a significant decrease in the ‘shift’
which confirms that the iNOS probe binding increases
upon LPS stimulation (Lane 4). In order to confirm the
specificity of Klf4 for the probe sequence, we also incu-
bated nuclear extracts in presence of 100-molar excess
of cold probe and observed a significant decrease in the
intensity of shifted bands (Lane 5) which indicate that
this probe is rather specific in nature. We can hereby
conclude from these experiments that Klf4 interacts
with iNOS promoter upon LPS induction. This is how
Klf4 may be directly upregulating iNOS production at
the transcriptional level itself thereby influencing the
production of NO.
Klf4 also regulates Cox-2 expression in microglia in
response to LPS
We have observed an increase in Cox-2 levels upon LPS
treatment; therefore we investigated whether Klf4 regu-
lates Cox-2 expression in microglial cells. RT-PCR for
Cox-2 was carried out with RNA isolated from control,
LPS, Si+LPS and Sc+LPS treated BV-2 cells. Interestingly,
we observed a significant reduction of Cox-2 mRNA in Si
+LPS cells when compared to LPS alone treated cells (p
< 0.05) (Fig 6A). We also found a significant 2-fold
reduction in Cox-2 protein levels in Si+LPS cells when
compared to LPS treated samples (p < 0.01) (Fig 6B).
Since the expression levels of Cox-2 decreased within 12
hours of LPS treatment upon Klf4 knockdown, it was
likely that this transcription factor directly interacted
with Cox-2 promoter in order to regulate and increase its
expression levels. Interaction of Klf4 to Cox-2 promoter
was evaluated using luciferase construct pCOX301-pGL2
which has Cox-2 promoter sequences upstream to firefly
luciferase gene. We found a significant increase in luci-
ferase activity in LPS and Sc+LPS cells (p < 0.01); how-
ever, in Si+LPS cells, luciferase activity significantly
decreased by 8-fold with respect to LPS and Sc+LPS cells
(p < 0.01) (Fig 6C). This finding suggests for the first
time that Klf4 also interacts with Cox-2 promoter in
addition to iNOS promoter in microglia upon endotoxin
stimulation. However, since no reports indicate the
known binding sequence of Klf4 on Cox-2 promoter, we
could not confirm its interaction by performing EMSA
u s i n gC o x - 2p r o b e s .I tw o u l db eo fi n t e r e s tt of i n do u t
the possible binding site for Klf4 on Cox-2 promoters
which would provide an insight into the mechanism of
Klf4 in terms of Cox-2 regulation.
Klf4 potentially interacts with pNF-kB
Endotoxins such as LPS have been known to activate
pNF-B which mediates several pro-inflammatory
pathways [11-13]. Klf4 binding sites have been reported
to be closer to pNF-B binding site on iNOS promoter
and also that it interacts with pNF-B [18]. Immunoblot
from total cellular extracts from BV-2 cells treated with
LPS for different time points of 3 h, 6 h and 12 h
showed a significant increase in pNF-B levels when
compared to untreated control cells(p < 0.05) (Fig 7A).
In order to investigate whether Klf4 interacts with pNF-
B in microglial cells upon LPS treatment, co-immuno-
precipitation was carried out with 100 μgo fn u c l e a r
extract using pNF-Ba n t i b o d ya n dt h eb l o t sw e r e
probed for Klf4 as well as for pNF-B. We found that
Klf4 was present in the immunoprecipitate that was pre-
pared using pNF-B antibody (Fig 7B). Rabbit IgG was
used as a control for this experiment. From our findings
we can infer that Klf4 interacts with pNF-Bu p o nL P S
stimulation. Whether this interaction is crucial for
transactivation of iNOS or Cox-2 promoters, a detailed
study is further required.
Discussion
Activation of microglia - which is marked by extensive
proliferation, chemotaxis, and altered morphology - is
the hallmark of neuroinflammation in several neurode-
generative diseases and pathological conditions of CNS.
It’s activation in response to LPS is well documented
[44,45] and it generates numerous pro- and anti-inflam-
matory mediators upon activation including IL-1b,
TNF-a, MCP-1 [9,46], IL-6 [47] and IL-10 [48] among
other immunomodulators. From various studies on
macrophages and microglia it is known that LPS binds
to TLR4 receptors and initiates a cascade leading to the
phosphorylation of NF-B which plays a major role in
inflammation in these cells [13,49]. However, inflamma-
tion is a complex process and, considering that several
pathways are upregulated upon endotoxin stimulation,
the role of other transcription factors and co-activators
cannot be ruled out in LPS-induced inflammation. In
this context, Klf4 has recently been identified as an
inflammatory gene upregulated in macrophages during
inflammation which has shown to be indispensable for
iNOS expression in human macrophages [18]. However,
reports on mouse macrophages have suggested that
increased Klf4 expression in response to LPS is not
associated with iNOS expression [30]. Since these stu-
dies were limited to peripheral system, it was important
therefore to investigate the role of Klf4 in the activation
of microglia to establish its involvement in neuroinflam-
mation. Our studies have demonstrated for the first
time in CNS that (i) Klf4 expression increases in micro-
glial cells with time upon LPS stimulation in vitro and
in vivo, (ii) Klf4 is involved in upregulation of pro-
inflammatory cytokines and key inflammatory mediators
including iNOS and Cox-2 and (iii) Klf4 interacts with
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activity.
At present, there are no known Klf4 knockout models
available as Klf4
-/- mice do not survive and die shortly
after birth due to defect in epithelial differentiation and
barrier formation [21,22]. Therefore, understanding the
mechanism underlying the activation of Klf4 is limited
to in vitro work. In tissues isolated from brains, we
observed that Klf4 expression increases in response to
LPS. Onset of inflammation in mouse brain was con-
firmed by an increase in pNF-B and pro-inflammatory
cytokines (data not shown) upon LPS treatment.
Figure 6 Role of Klf4 in Cox-2 expression. (A) Semi-quantitative RT-PCR of Cox-2 mRNA indicates a significant decrease in Si+LPS cells
compared to LPS-treated cells (B) Immunoblot for Cox-2 in total protein isolates from BV-2 cells. The protein levels of Cox-2 were also found to
be significantly reduced within 12 h of LPS treatment in Si+LPS cells compared to LPS-treated cells. The graphs represent relative Cox-2 mRNA
and protein levels with respect to the control samples. (C) Luciferase assay for Cox-2 promoter activity using a pCOX301/pGL2 construct. This
construct has the luciferase gene directly regulated by Cox-2 promoter. There is a significant reduction in luciferase activity in the Si+LPS
condition compared to the LPS-alone condition, indicating that Klf4 may be involved in regulating Cox-2 promoter activity. *, **, Statistical
differences in comparison to control values and #, Statistical differences in comparison to LPS-treated values. (* p < 0.05, ** p < 0.01, # p < 0.01).
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from P0-P2 BALB/c pups where LPS stimulation
increased the Klf4 expression at earlier time points. A
role for Klf4 in mediating inflammation could not be
confirmed by these studies, which were limited to
observing the expression of Klf4 in response to the bac-
terial endotoxin. We used BV-2 microglial cells to per-
form experiments where a transient knockdown was
comparatively feasible to perform without any significant
cell death. Our data suggest that expression of Klf4
Figure 7 Klf4 interacts with pNF-B during inflammation. (A) Immunoblot analysis of pNF-B levels from total cellular extracts upon LPS
treatment of BV-2 cells. The graph represents pNF-B levels relative to untreated control sample at different time points. There is a significant
increase in pNF-B expression at all time points of LPS treatment compared to control. (B) Immunoblot and immunoprecipitation analysis of the
interaction between pNF-B and Klf4 in nuclear extracts of differently treated cells. Samples were ‘pulled’ down with a pNF-B antibody. Lane A
shows the blot for Klf4 in the upper panel and for pNF-B in the lower panel in immunoprecipitate using anti-pNF-B antibody, and lane B
shows the same for immunoprecipitate using rabbit IgG as a control. *, **, Statistical differences in comparison to control values (* p < 0.05, ** p
< 0.01).
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Page 16 of 20increases upon LPS stimulation in a time and dose
dependent manner in these microglial cells as well. Our
observations for nuclear translocation studies suggest
that Klf4 migrates to the nucleus upon endotoxin stimu-
lation as early as 1 h after stimulation, and it is main-
tained at increased levels with respect to unstimulated
control cells even at later time points. Keeping in mind
the differences in either their cell cycle kinetics or
response to inflammatory stimuli, minor discrepancies
in the time kinetics of Klf4 nuclear localization between
BV-2 cells and primary microglia were anticipated.
It is likely that Klf4 remains stored in the cytoplasm
and its expression increases and it translocates to
nucleus after LPS stimulation. Immunofluorescence
images from BV-2 cells reveal that Klf4 is concentrated
within specific regions of the nucleus which may be
n u c l e o l i[ 5 0 ] .S of a r ,m a n yK rüppel-type transcription
factors have been found to be associated with nucleoli
[51,52]. However, the roles of the nucleolar-targeted
Krüppel-type zinc-finger proteins are not well known
[50]. Considering the role of Klfs as transcription factors
in acetylation reactions, it is also likely that they are
localized into specialized regions of active transcription
and are involved in differential acetylation of target
genes [53]. Our findings indicate a possible role of Klf4
as a transcription factor in response to endotoxin stimu-
lation. Most importantly, the expression of this tran-
scription factor corresponded with that of key
inflammatory enzymes, iNOS and Cox-2 as well as pro-
inflammatory cytokines including TNF-a,M C P - 1a n d
IL-6. Analysis of protein and tissues isolated from LPS
treated mice also confirmed an increase in Klf4 with
respect to control upon LPS administration.
iNOS is an important mediator of inflammation that
catalyzes the production of nitric oxide (NO) which,
under physiological conditions, can regulate vasocon-
striction. NO also acts as a neurotransmitter in the CNS
and has protective functions in anti-inflammatory path-
ways. However, at high concentrations NO readily reacts
with superoxide ion (∙ O2
-)t op r o d u c ep e r o x y n i t r i t e
(ONOO
-) which causes irreversible damage to lipids and
proteins resulting in cell death [54] and can therefore
potentially be neurotoxic [55]. However, the mechan-
isms of neuronal death are complex and not very well
understood [56]. The role of NF-Bi nt h eL P S -
mediated upregulation of iNOS is well established
[ 5 , 1 6 ] .F o rt h ef i r s tt i m e ,w eh a v es h o w nt h a tK l f 4i s
indispensable for iNOS expression in microglial cells.
However, in agreement with studies on iNOS expression
b yK l f 4i nh u m a nm a c r o p h a g e s ,w eh a v es h o w nan o v e l
regulation of iNOS expression and subsequent NO pro-
duction in microglia upon LPS stimulation. Klf4 knock-
down resulted in decreased iNOS mRNA and protein
expression within 12 hours of LPS treatment. This
decrease in iNOS levels also correlated with a significant
decrease in NO production observed in Si+LPS cells.
Luciferase assays revealed that Klf4 interacts with iNOS
promoter elements and upregulates iNOS expression
upon LPS stimulation in microglial cells. Gel shift stu-
dies with biotinylated probe showed that Klf4 binds to
-212 bp on iNOS promoter site in microglial cells upon
LPS treatment. Given these observations, we suggest a
possible role for Klf4 in iNOS expression and subse-
quent NO release in microglia and provide a novel
mechanism for their upregulation in the presence of
LPS. However, further studies are required in order to
understand the detailed mechanism of Klf4 in iNOS-
mediated neuronal death.
Cox-2 is another inflammatory enzyme, which cata-
lyzes the rate-limiting step in the inducible production
of prostaglandins like PGE2 [34] from arachidonic acid,
which is then converted to active prostanoids by
synthases [57]. The expression of Cox-2 requires bind-
ing of several cis-acting elements to Cox-2 promoters
[58] and NF-B plays a major role in the upregulation
of Cox-2 and subsequent prostanoids generation
[59-61]. The relationship between Cox-2 and Krüppel-
like factors was not known until recent studies sug-
gested that Cox-2 derived PGE2 may collaborate with
Klf4 or Klf5 to regulate the activation of the comple-
ment system and exert diverse effects on the intestinal
epithelium [62]. Since our findings suggest that Klf4
binds closer to the pNF-B site on the iNOS promoter,
and given that Cox-2 also has pNF-Bb i n d i n g
sequences on its promoter, we then studied the effect of
Klf4 knockdown on Cox-2 expression. Interestingly, we
saw a significant decrease in Cox-2 mRNA and protein
levels within 12 h of LPS stimulation upon Klf4 knock-
down. Promoter assays revealed that Klf4 interacts with
Cox-2 promoters, which make Klf4 upregulation indis-
pensable for Cox-2 expression in response to LPS sti-
mulation. However, the exact sequences to which Klf4
binds on a Cox-2 promoter are not known. It would be
of high interest to define possible binding sites for Klf4
on the Cox-2 promoter. Our finding is important con-
sidering the essential role played by Cox-2 in mediating
neuroinflammation. However, we are not sure if Klf4
expression also mediates the production of PGE2 via
Cox-2 upregulation. Its role in PGE2 production still
needs to be determined.
All the existing studies have focused on the putative
role of TNF-a,I F N - g [18,30] and IL-1b [63] on the
expression of Klf4. Moreover, the upregulation of several
of these pro-inflammatory cytokines depends on NF-B
activation [13,49,64]. Therefore, in addition to under-
standing the role of Klf4 in mediating iNOS and COX-2
expression, we also determined its role in regulating the
expression of pro-inflammatory cytokines. Our findings
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Page 17 of 20suggest that the expression of pro-inflammatory cyto-
kines TNF-a, MCP-1 and IL-6 is also modulated by
Klf4 in order to maintain a state of activation in micro-
glial cells. We observed a significant decrease in the
levels of these pro-inflammatory cytokines in Si+LPS
cells which were significantly higher in LPS treated cells
with respect to untreated controls. Further studies may
be required in order to understand in detail the
mechanism of Klf4-mediated cytokine release. These
studies will provide a better understanding of how
inflammation can be modulated by Klf4-mediated
microglial activation. Overexpression studies using Klf4
constructs can also be carried out to further evaluate
the extent of involvement of Klf4 in mediating
inflammation.
Our findings prompt us to believe that Klf4 is a pleio-
tropic transcription factor which plays a key role in the
establishment of neuroinflammation. The mechanisms
of pro-inflammatory cytokine regulation by Klf4 are not
clearly understood. Since pNF-Bi si n v o l v e di nt h e
expression of these cytokines [5], it is likely that Klf4
acts as a binding partner to pNF-B in co-operatively
upregulating pro-inflammatory cytokines. Our co-immu-
noprecipitation studies confirm that Klf4 interacts with
pNF-B, and this result is in agreement with previously
reported studies [18]. It is therefore possible that most
of the pro-inflammatory activities that involve pNF-B
may have Klf4 as a potential binding partner and Klf4
activation might employ a similar pathway to that of
pNF-B. Given that Klf4 plays an important role in cell
differentiation and proliferation, involvement of multiple
pathways in Klf4 expression cannot be ruled out.
Further studies, including overexpression of Klf4, will
therefore be required for a full understanding of this
transcription factor, which promises to be a potent tar-
get for therapeutic agents aiming to alleviate inflamma-
tion in brain.
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